These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38450511)

  • 41. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease.
    Hu X; Fan J; Ma Q; Han L; Cao Z; Xu C; Luan J; Jing G; Nan Y; Wu T; Zhang Y; Wang H; Zhang Y; Ju D
    J Nanobiotechnology; 2022 May; 20(1):237. PubMed ID: 35590366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Podocyte protection by Angptl3 knockout via inhibiting ROS/GRP78 pathway in LPS-induced acute kidney injury.
    Ma Y; Liu J; Liu H; Han X; Sun L; Xu H
    Int Immunopharmacol; 2022 Apr; 105():108549. PubMed ID: 35086056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4.
    Sonnenburg WK; Yu D; Lee EC; Xiong W; Gololobov G; Key B; Gay J; Wilganowski N; Hu Y; Zhao S; Schneider M; Ding ZM; Zambrowicz BP; Landes G; Powell DR; Desai U
    J Lipid Res; 2009 Dec; 50(12):2421-9. PubMed ID: 19542565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content.
    Pinzon Grimaldos A; Pacella I; Bini S; Tucci G; Cammarata I; Di Costanzo A; Minicocci I; D'Erasmo L; Arca M; Piconese S
    Atherosclerosis; 2022 Dec; 362():38-46. PubMed ID: 36253169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice.
    Li X; Zhang Y; Zhang M; Wang Y
    Sci Rep; 2020 Sep; 10(1):16168. PubMed ID: 32999434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Silico Description of the Direct Inhibition Mechanism of Endothelial Lipase by ANGPTL3.
    Montavoci L; Ben Mariem O; Saporiti S; Laurenzi T; Palazzolo L; Ossoli AF; Guerrini U; Calabresi L; Eberini I
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
    Surma S; Romańczyk M; Filipiak KJ
    Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism.
    Burks KH; Xie Y; Gildea M; Jung IH; Mukherjee S; Lee P; Pudupakkam U; Wagoner R; Patel V; Santana K; Alisio A; Goldberg IJ; Finck BN; Fisher EA; Davidson NO; Stitziel NO
    J Lipid Res; 2024 Feb; 65(2):100500. PubMed ID: 38219820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
    Xiao HB; Liang L; Luo ZF; Sun ZL
    Eur J Pharmacol; 2018 Oct; 836():122-128. PubMed ID: 30096295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential regulation and properties of angiopoietin-like proteins 3 and 4.
    Ge H; Cha JY; Gopal H; Harp C; Yu X; Repa JJ; Li C
    J Lipid Res; 2005 Jul; 46(7):1484-90. PubMed ID: 15863837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical angiopoietin-like protein that regulates ANGPTL3.
    Quagliarini F; Wang Y; Kozlitina J; Grishin NV; Hyde R; Boerwinkle E; Valenzuela DM; Murphy AJ; Cohen JC; Hobbs HH
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19751-6. PubMed ID: 23150577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
    Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
    J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
    D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
    Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of triglyceride metabolism by Angiopoietin-like proteins.
    Mattijssen F; Kersten S
    Biochim Biophys Acta; 2012 May; 1821(5):782-9. PubMed ID: 22063269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aggressive fibromatosis-like tumour with ANGPTL2::USP6 fusion.
    Mejbel HA; Morris J; Bahrami A
    Histopathology; 2024 Jun; 84(7):1243-1245. PubMed ID: 38379048
    [No Abstract]   [Full Text] [Related]  

  • 56. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.
    Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H
    J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imaging the ANGPTL3/8-mediated regulation of lipoprotein lipase in the heart.
    Yang Y; Jung H; Konrad RJ; Fong LG; Young SG
    J Lipid Res; 2023 Dec; 64(12):100467. PubMed ID: 37898405
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification of a mammalian angiopoietin-related protein expressed specifically in liver.
    Conklin D; Gilbertson D; Taft DW; Maurer MF; Whitmore TE; Smith DL; Walker KM; Chen LH; Wattler S; Nehls M; Lewis KB
    Genomics; 1999 Dec; 62(3):477-82. PubMed ID: 10644446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes.
    Essalmani R; Susan-Resiga D; Chamberland A; Asselin MC; Canuel M; Constam D; Creemers JW; Day R; Gauthier D; Prat A; Seidah NG
    J Biol Chem; 2013 Sep; 288(37):26410-8. PubMed ID: 23918928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.